Literature DB >> 75839

Prevention of experimental allergic encephalitis in guinea-pigs with spinal cord protein: optimum pretreatment schedules and appraisal of plausible mechanisms.

C F Macpherson, H Armstrong, O Tan.   

Abstract

Pretreatment of Hartley guinea-pigs with three injections of 100 microgram of the purified bovine spinal cord protein, (SCP), protected tham from clinical experimental allergic encephalitis (EAE) when they were subsequently challenged with 50 microgram of purified bovine myelin basic protein (MyBP) in Freund's complete adjuvant (FCA). The length of the optimum pretreated schedule was found to be 1 week and the animals were fully protected for 2 weeks. Protection declined thereafter so that by 4 weeks following pretreatment only 40% of the animals were protected. The protected state could be restored several weeks after it had lapsed by repeating the treatment with SCP. Immature animals did not respond well to pretreatment with SCP. Evidence was presented to indicate that specific, non-specific immune suppression or anti-SCP IgG were not involved to a significant extent in protection. SCP-treated guinea-pigs regularly displayed delayed skin hypersensitivity to MyBP after sensitization but there was no correlation between the degree of cutaneous reactivity and protection from disease. Because SCP is localized in the nerve axon, the speculation was advanced that anti-SCP blocking factors might be responsible for preserving axonal function in SCP-treated animals sensitized with MyBP.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 75839      PMCID: PMC1445351     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  15 in total

1.  ENCEPHALITOGEN-INDUCED INHIBITION OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS: PREVENTION, SUPPRESSION AND THERAPY.

Authors:  E C ALVORD; C M SHAW; S HRUBY; M W KIES
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Clinico-pathologic correlations in experimental allergic encephalomyelitis. II. Development of an index for quantitative assay of encephalitogenic activity of antigens.

Authors:  E C ALVORD; M W KIES
Journal:  J Neuropathol Exp Neurol       Date:  1959-07       Impact factor: 3.685

3.  Suppression of experimental allergic encephalomyelitis by stress.

Authors:  S LEVINE; R STREBEL; E J WENK; P J HARMAN
Journal:  Proc Soc Exp Biol Med       Date:  1962-02

Review 4.  Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

5.  Studies on brain antigens. VI. Prevention of experimental allergic encephalomyelitis by a water-soluble spinal cord protein, 1 -SCP.

Authors:  C F MacPherson; S L Yo
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

6.  Immune protection against experimental autoimmune encephalomyelitis: optimal conditions and analysis of mechanism.

Authors:  A Coates; I R Mackay; M Crawford
Journal:  Cell Immunol       Date:  1974-06       Impact factor: 4.868

7.  Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species.

Authors:  G E Deibler; R E Martenson; M W Kies
Journal:  Prep Biochem       Date:  1972

8.  Antigen-induced inhibition of experimental allergic encephalomyelitis. I. Inhibition in guinea pigs injected with non-encephalitogenic modified myelin basic protein.

Authors:  R H Swanborg
Journal:  J Immunol       Date:  1972-09       Impact factor: 5.422

9.  Studies on brain antigens. V. Purification and partial characterization of an anti-encephalitogenic spinal cord protein (SCP).

Authors:  S L Yo; C F MacPherson
Journal:  J Immunol       Date:  1972-11       Impact factor: 5.422

10.  The use of specific "lymphocyte" antisera to inhibit hypersensitive reactions of the "delayed" type.

Authors:  B H WAKSMAN; S ARBOUYS; B G ARNASON
Journal:  J Exp Med       Date:  1961-12-01       Impact factor: 14.307

View more
  3 in total

1.  Immunohistological localization of the anti-encephalitogenic bovine spinal cord protein (BSCP) in axons.

Authors:  C F MacPherson; A C Wallace
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

2.  Suppression and treatment of experimental allergic encephalitis in guinea-pigs with the bovine spinal cord protein (BSCP).

Authors:  C F MacPherson
Journal:  Immunology       Date:  1980-07       Impact factor: 7.397

3.  One-way humoral immune cross-reactivity between bovine spinal cord protein and bovine myelin basic protein.

Authors:  P Prokopchuk; B Ziola; I A Ramshaw; C F MacPherson
Journal:  Mol Immunol       Date:  1984-10       Impact factor: 4.407

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.